PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33212192-1	2021	Nerve agent exposure is generally treated by an antidote formulation composed of a muscarinic antagonist, atropine sulfate (ATR), and a reactivator of acetylcholinesterase (AChE) such as pralidoxime, obidoxime (OBI), methoxime, trimedoxime or HI-6 and an anticonvulsant.	pralidoxime	187-198	acetylcholinesterase	Cavia porcellus	173-177	
3181042-2	1988	The logarithm of the percentage RBC AChE reactivated by 2-PAM after soman exposure was plotted as a function of time.	pralidoxime	56-61	acetylcholinesterase	Cavia porcellus	36-40	
31954867-3	2020	Three common oximes are available: HI-6, Pralidoxime (2-PAM) and Obidoxime (Obi), all possess a nucleophile that can break the NA-AChE covalent bond.	pralidoxime	41-52	acetylcholinesterase	Cavia porcellus	130-134	
19763542-1	2009	Methoxime (MMB-4) is a leading candidate oxime acetylcholinesterase (AChE) reactivator to replace pralidoxime (2-PAM) for therapeutic treatment of nerve agent intoxication.	pralidoxime	98-109	acetylcholinesterase	Cavia porcellus	47-67	
21989207-1	2011	AIMS: Due to pralidoxime chloride"s (2-PAM) positive charge, it"s penetration through the blood brain barrier (BBB) and reactivation of organophosphate (OP) inhibited central nervous system (CNS) acetylcholinesterase (AChE) is poor.	pralidoxime	13-33	acetylcholinesterase	Cavia porcellus	196-216	
21989207-1	2011	AIMS: Due to pralidoxime chloride"s (2-PAM) positive charge, it"s penetration through the blood brain barrier (BBB) and reactivation of organophosphate (OP) inhibited central nervous system (CNS) acetylcholinesterase (AChE) is poor.	pralidoxime	13-33	acetylcholinesterase	Cavia porcellus	218-222	
20156430-2	2010	Standard OP exposure therapy in the United States consists of atropine sulfate (to block muscarinic receptors), the acetylcholinesterase (AChE) reactivator (oxime) pralidoxime chloride (2-PAM), and a benzodiazepine anticonvulsant to ameliorate seizures.	pralidoxime	164-184	acetylcholinesterase	Cavia porcellus	138-142	
19680820-1	2010	The capability of the tertiary oximes, monoisonitrosoacetone (MINA) and diacetylmonoxime (DAM), to reactivate acetylcholinesterase (AChE) inhibited by sarin (GB) in the blood, brain, and peripheral tissues of guinea pigs was compared with that of the quaternary oximes 2-PAM, HLo7, and MMB-4.	pralidoxime	269-274	acetylcholinesterase	Cavia porcellus	110-130	
19680820-1	2010	The capability of the tertiary oximes, monoisonitrosoacetone (MINA) and diacetylmonoxime (DAM), to reactivate acetylcholinesterase (AChE) inhibited by sarin (GB) in the blood, brain, and peripheral tissues of guinea pigs was compared with that of the quaternary oximes 2-PAM, HLo7, and MMB-4.	pralidoxime	269-274	acetylcholinesterase	Cavia porcellus	132-136	
19763542-1	2009	Methoxime (MMB-4) is a leading candidate oxime acetylcholinesterase (AChE) reactivator to replace pralidoxime (2-PAM) for therapeutic treatment of nerve agent intoxication.	pralidoxime	98-109	acetylcholinesterase	Cavia porcellus	69-73	
19763542-1	2009	Methoxime (MMB-4) is a leading candidate oxime acetylcholinesterase (AChE) reactivator to replace pralidoxime (2-PAM) for therapeutic treatment of nerve agent intoxication.	pralidoxime	111-116	acetylcholinesterase	Cavia porcellus	47-67	
19763542-1	2009	Methoxime (MMB-4) is a leading candidate oxime acetylcholinesterase (AChE) reactivator to replace pralidoxime (2-PAM) for therapeutic treatment of nerve agent intoxication.	pralidoxime	111-116	acetylcholinesterase	Cavia porcellus	69-73	
19778238-3	2009	Oximes such as 2-PAM are used to reactivate OP-inhibited AChE so as to restore normal enzymatic function and serve as a true antidote.	pralidoxime	15-20	acetylcholinesterase	Cavia porcellus	57-61